Inhale-3 Study Findings to be Presented at ADA's 84th Scientific Sessions

June 05, 2024 – MannKind Corporation, a company focused on developing and commercializing innovative inhaled therapeutic products, will present the 17-week endpoint results from the INHALE-3 study during the American Diabetes Association’s (ADA) 84th Scientific Sessions. The results will be showcased in a 90-minute symposium and livestream on Saturday, June 22.

The presentation will be led by Dr. Irl B. Hirsh, Chair of the INHALE-3 Study Protocol, along with the investigational team. Dr. Roy W. Beck, founder of Jaeb Center, will moderate the session. MannKind’s CEO, Michael Castagna, expressed excitement about the upcoming results, highlighting it as the largest post-market clinical trial with Afrezza in the last decade. The study aims to answer how inhaled insulin compares to traditional insulin treatment methods.

The symposium, titled "The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Injections in Adults with Type 1 Diabetes," will be held on Saturday, June 22, 2024, from 8:00 to 9:30 AM (ET). The presentation will include several key topics and speakers:

1. Inhaled Insulin’s History and Study Rationale – Dr. Halis Akturk
2. Study Methods & Participant Baseline Characteristics – Dr. Yogish Kudva
3. Study Results I: Comparison of Inhaled Insulin vs. Rapid Acting Analogue Insulin in Users of AID or MDI During Standardized In-Clinic Meal Challenge – Dr. Ruth S. Weinstock
4. Study Results II: Primary Efficacy, Safety, and Quality of Life Outcomes – Dr. Carol J. Levy
5. Study Results III: Effect of Inhaled Insulin-Degludec Compared with AID and in Subgroups According to Participant Characteristics – Dr. Grazia Aleppo
6. Critique of Study Design and Results – Dr. Irl B. Hirsch
7. Use of Afrezza in Clinical Practice – Dr. Thomas Blevins

The symposium will conclude with a Question and Answer Session, moderated by Dr. Roy W. Beck. Attendees can join the presentation in person at W320 Chapin Theatre at the Orange County Convention Center or through a livestream.

In addition to the symposium, MannKind Corporation will maintain a presence at booth #1307 in the Exhibit Hall throughout the ADA Scientific Sessions. The company's Clinical Education Team will be available for scientific discussions and to provide further information about their ongoing research and products.

MannKind Corporation is dedicated to addressing unmet medical needs through the development of inhaled therapeutic products and devices. The company focuses on diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Their flagship technologies, which include dry-powder formulations and inhalation devices, offer rapid and convenient drug delivery to the deep lung, potentially providing both local and systemic benefits.

The corporation's mission is to empower individuals to manage their health conditions more effectively and enjoy a better quality of life. MannKind’s efforts are supported by a nationwide team committed to advancing their innovative solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!